Literature DB >> 1312070

An ocular model of adenovirus type 5 infection in the NZ rabbit.

Y J Gordon1, E Romanowski, T Araullo-Cruz.   

Abstract

Ocular adenoviral infections occur worldwide, and currently, there is no ocular animal model for evaluating new antivirals or studying pathogenesis. With a paired-eye design, an ocular model was developed in 32 New Zealand rabbits following topical and intrastromal inoculation with a clinical isolate of adenovirus type 5 (Ad5 McEwen). Clinical signs of infection--conjunctivitis, corneal edema, subepithelial infiltrates, and iritis--and seroconversion were evaluated. Replicating virus on the ocular surface was determined by serial ocular titers. Reproducible acute ocular infection was demonstrated in 32 of 32 infected eyes (100%), with mean viral replication lasting for 8.3 days. Peak ocular viral titers (10(3) plaque forming units/ml) were achieved on day three after inoculation and represented a 2 log increase (100 times) over day one. Ocular viral replication was associated with acute conjunctivitis (24/34 eyes, 75%), and delayed-onset presumed immune-mediated clinical disease was associated with: blepharoconjunctivitis (21/32 eyes, 66%), iritis (29/32 eyes, 91%), corneal edema (32/32 eyes, 100%), and subepithelial corneal infiltrates (30/32 eyes, 94%). Seroconversion was demonstrated in 26 of 31 rabbits (84%). The study concludes that a potentially useful animal model of adenoviral ocular infection can be attained.

Entities:  

Mesh:

Year:  1992        PMID: 1312070

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  14 in total

1.  Benzalkonium Chloride Demonstrates Concentration-Dependent Antiviral Activity Against Adenovirus In Vitro.

Authors:  Eric G Romanowski; Kathleen A Yates; Robert M Q Shanks; Regis P Kowalski
Journal:  J Ocul Pharmacol Ther       Date:  2019-04-10       Impact factor: 2.671

Review 2.  Genomic foundations of evolution and ocular pathogenesis in human adenovirus species D.

Authors:  Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh
Journal:  FEBS Lett       Date:  2019-12-11       Impact factor: 4.124

3.  Mouse adenovirus type 1 infection in SCID mice: an experimental model for antiviral therapy of systemic adenovirus infections.

Authors:  L Lenaerts; E Verbeken; E De Clercq; L Naesens
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Human adenovirus type 37 and the BALB/c mouse: progress toward a restricted adenovirus keratitis model (an American Ophthalmological Society thesis).

Authors:  James Chodosh
Journal:  Trans Am Ophthalmol Soc       Date:  2006

Review 5.  Ocular tropism of respiratory viruses.

Authors:  Jessica A Belser; Paul A Rota; Terrence M Tumpey
Journal:  Microbiol Mol Biol Rev       Date:  2013-03       Impact factor: 11.056

6.  Establishment of a cottontail rabbit papillomavirus/HLA-A2.1 transgenic rabbit model.

Authors:  Jiafen Hu; Xuwen Peng; Lynn R Budgeon; Nancy M Cladel; Karla K Balogh; Neil D Christensen
Journal:  J Virol       Date:  2007-04-25       Impact factor: 5.103

7.  Efficacy of topical immunoglobulins against experimental adenoviral ocular infection.

Authors:  Edward C Nwanegbo; Eric G Romanowski; Y Jerold Gordon; Andrea Gambotto
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

8.  Chemokine CXCL1/KC and its receptor CXCR2 are responsible for neutrophil chemotaxis in adenoviral keratitis.

Authors:  Ashish V Chintakuntlawar; James Chodosh
Journal:  J Interferon Cytokine Res       Date:  2009-10       Impact factor: 2.607

Review 9.  Mystery eye: Human adenovirus and the enigma of epidemic keratoconjunctivitis.

Authors:  Rahul A Jonas; Lawson Ung; Jaya Rajaiya; James Chodosh
Journal:  Prog Retin Eye Res       Date:  2019-12-28       Impact factor: 21.198

Review 10.  Emerging antiviral therapeutics for human adenovirus infection: Recent developments and novel strategies.

Authors:  Mackenzie J Dodge; Katelyn M MacNeil; Tanner M Tessier; Jason B Weinberg; Joe S Mymryk
Journal:  Antiviral Res       Date:  2021-02-10       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.